Dear healthcare professional, we are committed to respect the SFDA Disclosure and Transparency Initiative Guide #65925 (the Guide), which requires transparency with regards to financial relationships between pharmaceutical/medical firms and healthcare professionals (HCPs) as well as healthcare institutions (HCIs) operating in Kingdom of Saudi Arabia. To meet these requirements, GSK must disclose any transfer of value/service provided by GSK to HCPs/HCIs to the SFDA while also adhering to the applicable privacy regulations in the Kingdom of Saudi Arabia. By signing disclosure, you give your consent to GSK to process your personal data for meeting the requirements of the guide and disclose the listed information to meet the SFDA transparency requirements. If you do not grant your consent or later withdraw your consent, GSK will regret to include you at any of its activities or services to ensure full alignment with local authorities regulations. Disclosure will start for any transfer of value/service from GSK as of October 1st, 2018 as per SFDA requirements. In case of consent withdrawal, GSK will still be committed to SFDA requirements of disclosure during the period of consent. If you wish to access or correct any of your information held or disclosed by GSK or withdraw your consent, you may get in contact with the “Authorized Representative” of GSK through the e-mail address below: email@example.com .